Contact us

Tablets CDMO Companies
Tablets Contract Manufacturing Services

Your Trusted Partners for Tablets Contract Manufacturing and Development

Showing 47 facilities
Laboratorio REIG JOFRE, SA (TOLEDO PLANT)
Spain

Laboratorio REIG JOFRE, SA (TOLEDO PLANT)

LABORATORIO REIG JOFRE SA

Betalactam antibiotics (FDF) development and manufacturing state-of-the-art facilities.

MARKETS: EMA (EU), ANVISA (Brazil), ISP (Chile), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), INVIMA (Colombia), SFDA (Saudi Arabia), TGA (Australia)

REGION: APAC, MENA, LATAM, Europe, North America

COMPLIANCE: DIGEMID, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP)

BATCH SIZE: Large, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (J) Antiinfectives for systemic use

CONTROLLED SUBSTANCES: Lowest potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Upperton Pharma Solutions
United Kingdom

Upperton Pharma Solutions

Upperton Pharma Solutions

Development and manufacturing of oral solid dose (OSD), nasal, inhalation, and sterile dry powders and liquids drug products.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), FDA (USA), Health Canada (Canada), MHRA (UK), TGA (Australia)

REGION: Europe

USE: Human

CATEGORY / PRODUCT: OLIGONUCLEOTIDES, BIOLOGICS, SERVICES, FDF / DRUG PRODUCTS

BSL (Biological Safety Level): 1

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (N) Nervous system, (R) Respiratory system

BATCH SIZE: Small, Medium

COMPLIANCE: MHRA (UK GMP)

Avara Pharmaceutical Services | Arecibo Site
United States

Avara Pharmaceutical Services | Arecibo Site

AVARA

Commercial-scale oral solid dosage (OSD) manufacturing facility with strong expertise in controlled substances (DEA II V).

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

COMPLIANCE: ICH, FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), EMA (EU GMP), Health Canada (Canada GMP), MFDS/KFDA (Republic of Korea GMP)

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), Russian Health Authorities, MFDS (South Korea), TGA (Australia)

BATCH SIZE: Large, Medium

USE: Human

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, SERVICES, FDF / DRUG PRODUCTS, PARTICLE ENGINEERING

SERVICES: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (S) Sensory organs, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

REGION: North America

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Avara Pharmaceutical Services | Norman Site
United States

Avara Pharmaceutical Services | Norman Site

AVARA

Contract manufacturing facility specialized in Oral Solid Dosage (OSD) for clinical and commercial supply.

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

COMPLIANCE: ICH, FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), Health Canada (Canada), ANVISA (Brazil), Russian Health Authorities, MHRA (UK), MFDS (South Korea), TGA (Australia)

BATCH SIZE: Large, Small, Medium

USE: Human

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, SERVICES, FDF / DRUG PRODUCTS, PARTICLE ENGINEERING

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (S) Sensory organs, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

REGION: North America

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Sidefarma
Portugal

Sidefarma

Sidefarma SA

CMO specialized in the manufacture of small and medium size batches for pharmaceutical companies across the world in regulated markets.

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), Health Canada (Canada), DIGEMID (Peru), MHRA (UK), SFDA (Saudi Arabia), Turkish Health Authorities, EDE (UAE), TGA (Australia)

REGION: Europe

COMPLIANCE: ISO, UAE Ministry of Health & Prevention, EMA (EU GMP)

USE: Human

SERVICES: Manufacturing services, Analytical / QC services, Quality Assurance services, Packaging

BATCH SIZE: Small, Medium

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

FAES FARMA | DERIO facility
Spain

FAES FARMA | DERIO facility

FAES FARMA

Developer and manufacturer of human medicinal products.

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), EDE (UAE), TGA (Australia)

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: DIGEMID, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), ECOVADIS, TGA (Australia GMP), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

OEB (Occupational Exposure Banding): 1 / low-hazard (PDE > 10,000 µg/day)

Aenova Group - Location Tittmoning, Germany
Germany

Aenova Group - Location Tittmoning, Germany

Aenova

Competence Center conventional solids high volume plant.

MARKETS: EMA (EU), FDA (USA), Health Canada (Canada), ANVISA (Brazil), Russian Health Authorities, TGA (Australia)

REGION: Europe

COMPLIANCE: FDA (cGMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TGA (Australia GMP), EMA (EU GMP), Health Canada (Canada GMP)

BATCH SIZE: Large, Medium

CATEGORY / PRODUCT: NUTRACEUTICALS, FDF / DRUG PRODUCTS

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Aenova Group - Location Sisseln, Switzerland
Switzerland

Aenova Group - Location Sisseln, Switzerland

Aenova

Competence Center complex conventional solids.

REGION: Europe

MARKETS: FDA (USA), ANVISA (Brazil), Russian Health Authorities, MFDS (South Korea), Turkish Health Authorities

COMPLIANCE: FDA (cGMP), ISO, ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), World Health Organization (GMP / HACCP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: NUTRACEUTICALS, FDF / DRUG PRODUCTS

USE: Human

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Aenova Group - Location Regensburg, Germany
Germany

Aenova Group - Location Regensburg, Germany

Aenova

Competence Center high potent solids (oncology) conventional solids - specialty semisolids & liquids.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), FDA (USA), ANVISA (Brazil), Russian Health Authorities, SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities

REGION: Europe

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), SFDA (Saudi Food & Drug Authority), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: COSMETICS, NUTRACEUTICALS, FDF / DRUG PRODUCTS, PARTICLE ENGINEERING

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

Aenova Group - Location Münster, Germany
Germany

Aenova Group - Location Münster, Germany

Aenova

Competence Center low-dosed high potent solids (hormones, hormone-like), low-dosed capsules.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), Russian Health Authorities, MFDS (South Korea), Turkish Health Authorities

REGION: Europe

COMPLIANCE: FDA (cGMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), EMA (EU GMP), MFDS/KFDA (Republic of Korea GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

THERAPEUTIC AREAS OF EXPERTISE (ATC): (H) Systemic hormonal preparations excl. sex hormones and insulins

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

Aenova Group - Location Marburg, Germany
Germany

Aenova Group - Location Marburg, Germany

Aenova

Competence Center complex conventional solids and narcotics.

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), Russian Health Authorities

REGION: Europe

COMPLIANCE: FDA (cGMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), EMA (EU GMP)

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: NUTRACEUTICALS, FDF / DRUG PRODUCTS

USE: Human

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

Aenova Group - Location Latina, Italy
Italy

Aenova Group - Location Latina, Italy

Aenova

Competence Center animal health products and sterile technologies.

MARKETS: EMA (EU), FDA (USA), ANVISA (Brazil), Russian Health Authorities, SFDA (Saudi Arabia), Turkish Health Authorities

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: Europe

COMPLIANCE: FDA (cGMP), ANVISA (Brazil B-GMP), Roszdravnadzor (Russia GMP), TITCK (Turkish Health Authorities), SFDA (Saudi Food & Drug Authority), EMA (EU GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1, 2

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+16 more facilities

Create free account

Tablets remain the most widely used pharmaceutical dosage form worldwide, offering convenience, stability, and cost-effectiveness. Whether you’re developing an immediate-release product or a complex modified-release formulation, working with trusted tablets CDMO companies ensures technical precision, compliance, and efficient scale-up.

With robust tablets contract manufacturing capabilities, these partners offer integrated services from formulation to commercial production — helping pharmaceutical and biotech companies deliver high-quality tablet-based therapies across global markets.


How to Choose Tablets CDMO Companies

When selecting among tablets CDMO companies, consider the following key factors:

  • Formulation expertise: Ability to develop IR, SR, ER, DR, and multilayer tablets
  • Technology access: Capabilities in dry granulation, wet granulation, roller compaction, and direct compression
  • Analytical and dissolution testing for regulatory compliance and release kinetics
  • Batch size flexibility for clinical, pilot, and commercial volumes
  • Containment capabilities for high-potency or moisture-sensitive APIs
  • Regulatory history: Approvals from FDA, EMA, PMDA, and other health agencies

The right CDMO will ensure consistent tablet performance and a smooth path to regulatory approval.


Key Services Offered by Tablets Contract Manufacturers

Professional tablets contract manufacturing companies offer a comprehensive range of services:

  • Pre-formulation and excipient selection
  • Tablet formulation and process development
  • Granulation (wet or dry) and blending
  • Compression and coating (film, enteric, sugar, functional)
  • Modified-release technologies including matrix, osmotic, and multiparticulate systems
  • Analytical method development and validation
  • Stability studies under ICH guidelines
  • GMP production for clinical and commercial supply
  • Packaging and serialization for global distribution

These services ensure your tablets are consistent in content, bioavailability, and patient experience.


Advantages of Partnering with Tablets CDMO Companies

Working with experienced tablets CDMO companies provides major benefits:

  • Cost-effective production with established tablet platforms
  • Fast scale-up from bench to commercial scale
  • Robust process validation for global regulatory compliance
  • High throughput capacity for large-market products
  • Custom solutions for unique formulations and delivery profiles

These CDMOs enable you to streamline development, improve quality, and accelerate time to market.


Tablets CDMO Companies

Some of the top tablets CDMO companies include:

  • Lannett: Oral Solid Dose (OSD) and Liquids. [See CDMO profile]
  • Pharmaloop (a Salvat company): Fully integrated CDMO solutions for Blow-Fill-Seal (BFS), sterile multidose, non-sterile multi-dose, sachets, capsules, and tablets. [See CDMO profile]
  • Reig Jofre: FDF development and manufacturing state-of-the-art facilities. [See CDMO profile]
  • Cenexi: Injectables manufacturing. [See CDMO profile]
  • FAES FARMA: Developer and manufacturer of human medicinal products. [See CDMO profile]
  • Cambrex: Specialized in the early development of small molecule pharmaceutical products in a fully integrated drug substance and finished forms contract manufacturing facility. [See CDMO profile]
  • Skyepharma: Fully integrated FDF CDMO. [See CDMO profile]
  • Huiyu Pharmaceuticals Co., Ltd: Development and production of complex and high-value dosage forms including implants, oral solids / OSD and sterile forms. [See CDMO profile]
  • Aenova Group: Competence center for conventional solids and clinical services. [See CDMO profile]
  • I+Med: Developer and manufacturer of new drug products with controlled release technologies. [See CDMO profile]
  • Adragos Pharma: Specialized in the manufacturing of oral liquids, semisolids, and oral solids / OSD. [See CDMO profile]
  • Glatt Pharmaceutical Services GmbH Co. & KG: cGMP-compliant CDMO offering end-to-end services in complex oral solid dosage forms. [See CDMO profile]
  • Darnytsia Kyiv: Manufacturing of oral liquids, semisolids, and OSD with stringent quality control. [See CDMO profile]
  • Adare Pharma: Turnkey product development and commercial manufacturing focused on oral dosage forms. [See CDMO profile]
  • Sidefarma: Specialized in small and medium batches of oral liquids, semisolids, and OSD. [See CDMO profile]

Related Information

You may also be interested in: